Ibero-American Consensus for the Management of Peritoneal Sarcomatosis : Updated Review and Clinical Recommendations
Muñoz-Casares, F.C. (San Juan de Dios Hospital)
Martín-Broto, Javier (Jimenez Diaz Foundation University Hospital)
López-Rojo, I. (Anderson Cancer Center Madrid)
González-Bayón, L. (Hospital General Universitario Gregorio Marañón)
Sebio, Ana (Institut de Recerca Sant Pau)
Serrano, Cesar (Hospital Universitari Vall d'Hebron)
Carvalhal, S. (Portuguese Institute of Oncology of Lisbon)
Lopes-Bras, R. (Lisboa North University Center)
Asencio, Jose Manuel (Hospital General Universitario Gregorio Marañón)
Cascales-Campos, Pedro (Hospital Clínico Universitario Virgen de la Arrixaca (El Palmar, Múrcia))
Torres-Melero, Juan (Hospital Universitario Torrecárdenas (Almeria, Andalusia))
Gómez-Barbadillo, José (San Juan de Dios Hospital)
Abreu de Souza, Joaquim (Portuguese Institute of Oncology of Porto)
Souza, Alexandre F. (Portuguese Institute of Oncology of Porto)
Flores-Ayala, Guillermo (Jalisco Institute of Cancerology)
Palacios Fuenmayor, Luis josé (Institute of Cancerology (IDC) Las Américas)
González López, José Antonio (Institut de Recerca Sant Pau)
Vasques, Hugo (Portuguese Institute of Oncology of Porto)
Universitat Autònoma de Barcelona. Departament de Medicina

Fecha:	2024
Resumen:	Peritoneal sarcomatosis is a rare malignant disease with a poor prognosis, secondary to peritoneal dissemination of abdominopelvic soft tissue sarcomas. Its rarity, together with the characteristic histological heterogeneity and the historically poor response to systemic treatments, has prevented the establishment of widely accepted treatment criteria with curative intent. In this sense, radical cytoreductive surgery (CRS) with peritonectomy procedures and hyperthermic intraperitoneal chemotherapy (HIPEC), widely used in peritoneal carcinomatosis with excellent results, have not had the same evolutionary development in patients with peritoneal sarcomatosis. A multidisciplinary working group of experts in sarcomas and peritoneal oncological surgery established a series of recommendations based on current scientific evidence for the management of peritoneal sarcomatosis, taking into account the different histological subgroups of abdominopelvic sarcomas that can cause it depending on their origin: retroperitoneal sarcomas, uterine sarcomas, and visceral/peritoneal sarcomas of GIST (gastrointestinal stromal tumor) and non-GIST origin. This article shows the results of sarcoma experts' voting on the recommendations presented during the I Ibero-American Consensus on the Management of Peritoneal Sarcomatosis, which took place during the recent celebration of the III Hispanic-Portuguese Meeting for Updates on the Treatment of Sarcomas.
Derechos:	Aquest document està subjecte a una llicència d'ús Creative Commons. Es permet la reproducció total o parcial, la distribució, la comunicació pública de l'obra i la creació d'obres derivades, fins i tot amb finalitats comercials, sempre i quan es reconegui l'autoria de l'obra original.
Lengua:	Anglès
Documento:	Article de revisió ; recerca ; Versió publicada
Materia:	Cytoreductive surgery ; Hyperthermic intraperitoneal chemotherapy ; Induction chemotherapy ; Peritoneal GIST ; Peritoneal sarcomatosis ; Peritonectomy procedures ; Soft tissue sarcoma ; Targeted therapy
Publicado en:	Cancers, Vol. 16, Num. 15 (August 2024) , art. 2646, ISSN 2072-6694

DOI: 10.3390/cancers16152646
PMID: 39123374

28 p, 398.0 KB

El registro aparece en las colecciones:
Documentos de investigación > Documentos de los grupos de investigación de la UAB > Centros y grupos de investigación (producción científica) > Ciencias de la salud y biociencias > Institut de Recerca Sant Pau
Artículos > Artículos de investigación
Artículos > Artículos publicados